Physicians' Academy for Cardiovascular Education
Member

Brain amyloid in later life increases with number of midlife vascular risk factors

Apr. 20, 2017 - Gottesman RF, et al. - JAMA 2017
Increasing numbers of midlife vascular risk factors obesity, smoking, hypertension, diabetes and high cholesterol associate with brain amyloid deposition in later life.

Increasing numbers of midlife vascular risk factors obesity, smoking, hypertension, diabetes and high cholesterol associate with brain amyloid deposition in later life.

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist.

Dr. Robert J Chilton, MD, argues that new diabetes treatments showing cardiovascular benefit require a different role of the cardiologist. The SGLT2 inhibitor empagliflozin, for example, shows both cardiovascular and renal protection, in addition to lowering glucose.

Personalised workouts to prevent heart disease designed by new digital instrument

Apr. 19, 2017 - news

The EXPERT tool specifies ideal exercise type, intensity, frequency, and duration needed to prevent a first or repeat cardiovascular event.

SGLT-2 inhibitor did not decrease risk of stroke in diabetic patients

Apr. 19, 2017 - Zinman B, et al. - Stroke. 2017

In diabetic patients at high cardiovascular risk, empagliflozin, when compared with placebo, was not associated with either a reduction or an increase in the risk of cerebrovascular events.

New meta-analysis on statin use in elderly

Apr. 18, 2017 - Ridker PM, et al. - Circulation, 2017

A new meta-analysis provide insights in statin use for primary prevention of the elderly, however, it also leaves critical questions unanswered that are relevant for clinical practice.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

Lower achieved SBP and DBP associated with more CV events

Apr. 12, 2017 - Böhm M, et al. - Lancet. 2017

In high CV risk patients, lowering SBP to less than 130 mmHg or DBP to less than 75 mmHg, associates with increased rates for CV death, myocardial infarction and heart failure, but not stroke.

Levels of natriuretic peptides related to therapeutic effect and CV outcomes in HFpEF patients

From the TOPCAT Trial

Apr. 12, 2017 - Anand IS, et al. - JACC, 2017

Natriuretic peptide levels in HFpEF patients associate with adverse outcomes and patients with low NP levels benefited from spironolactone therapy in particular.

Increased risk of acute MI on DOAC vs. VKA in real world AF patients

Apr. 12, 2017 - Stolk LM et al., - Br J Clin P harmacol 2017

Analysis of new users of rivaroxaban or dabigatran, aspirin and VKAs in CPRD reveals a two-fold increased risk of AMI in current users of DOAC or aspirin, as compared with VKA.

Heart failure patients are at higher risk for any type of stroke

Apr. 12, 2017 - Adelborg K, et al. - Stroke. 2017

In a large cohort study of 30 years, heart failure was associated with an increased risk of ischaemic stroke, intracerebral and subarachnoid haemorrhage, especially in the short term.

ANGPTL3 deficiency linked to reduced CAD risk

Apr. 11, 2017 - Stitziel NO, et al. - JACC 2017

Angiopoietin-like protein 3 mutations relate to coronary plaque, lower lipid and triglyceride levels and reduced CAD risk and levels of ANGPTL3 protein associate with risk for myocardial infarction.

Subspecies of HDL associated with anthropometrical measures and physical activity

Apr. 11, 2017 - Koch M, et al. - J Lipid Res. 2017
Subspecies of HDL (with or without apoC-III) were associated with lifestyle factors and anthropometrical measures such as waist and hip circumference, BMI and fat mass

Levels of HDL with or without apoC-III both associated differently with the amount of physical activity or anthropometrical measures, such as waist and hip circumference, BMI and fat mass.

3' education

E-counselling improves adherence in hypertensives

Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Troponin is an independent predictor of CV events at non-cardiac surgery

Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada

New diabetes treatments with CV benefit: A changing role for the cardiologist

Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

PCSK9 inhibitor safe for cognitive function, even at very low cholesterol levels

Mar. 19, 2017

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Get involved in May Measurement Month!

Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

Tailoring oral anticoagulation in elderly patients with AF

Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

How low to go with blood pressure: J-curve or not?

Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

Shifting priorities of care for older cardiac patients

Nov. 12, 2016 - New Orleans, LA, USA - Daniel E. Forman, MD (Pittsburgh, PA, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)

Advancing CV care of cancer patients: Where are we now?

Nov. 12, 2016 - New Orleans, LA, USA - Javid J. Moslehi, MD (Nashville, TN, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

Blood pressure control in CKD in older people

Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)

Emerging therapies and treatment strategies in pulmonary arterial hypertension

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USA

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

CAC reveals evidence of coronary artery calcification in third of low-risk women

Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands

Outstanding questions and ongoing studies on the use of NOACs

Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Lipid-lowering in the elderly - considering net benefit

Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

No added value of monitoring platelet function after ACS

Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany

No indication for difference in efficacy between potent platelet inhibitors after PCI

Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

New agents to treat hyperkalaemia

July 18, 2016 - ACC 2016 - Bertram Pitt, MD

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

Two additions to the therapeutic armory to treat HFrEF

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Statin lowers CV risk, in absence of LDL-c measurement

Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

10' education

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Oral anticoagulation in daily clinical practice in varous patient populations

Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Heart failure news at the ESC

Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##RIGHT_SECTION_ITEMS_FULL_TITLE##

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Beyond statins: The role of ezetimibe in targeting residual risk

Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Surviving elevated Lp(a): a patient story from diagnosis to treatment

May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The spectrum of Heart Failure

May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What surprises have emerged from genetic studies of coronary artery disease?

Apr. 25, 2016 - Boston, MA, USA - Dr. Sekar Kathiresan (Boston, MA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##RIGHT_SECTION_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

HF Summit : innovation in clinical care in heart failure

Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A multidisciplinary approach in heart failure management

Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##RIGHT_SECTION_ITEMS_FULL_TITLE##